-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
R&D base
23
2025-03
To celebrate World Book Day and foster the integration of learning with practical application, thereby further enhancing the overall quality and professional capabilities of all employees, Keyuan Grand Lecture Hall is specially launching the "Read One Book Together" guided reading activity on April 23. This initiative leverages the power of reading to drive personal growth, helping build a learning-oriented team committed to continuous, lifelong learning—and ultimately strengthening the company's intrinsic soft power.
2025-03-23
23
2025-03
Keyuan Pharmaceutical Wins the "2025 Forbes China Industry Development Innovation Brand Award"!
On March 22, the "2025 Forbes China Industry Development Leader Selection" was held in Shanghai. Shandong Keyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Keyuan Pharmaceutical"; stock code: 301281.SZ) was honored with the 2025 Forbes China Industry Development Innovation Brand Award, thanks to its outstanding innovation capabilities and significant industry influence. This prestigious award not only recognizes Keyuan Pharmaceutical's years of dedicated efforts in the chemical API and formulation sectors but also serves as a powerful testament to the company's ability to achieve transformative growth through innovation amid the ongoing global industrial restructuring.
2025-03-23
23
2025-03
On the 22nd, Keyuan Pharmaceutical successfully held its Q1 2025 Marketing Conference, themed "Embrace Productism, Focus on Precision Cultivation, Deeply Unlock Potential, Foster Systemic Collaboration, and Deliver Targeted Empowerment—Uniting All Employees to Drive Marketing Targets Toward Breakthrough Success." The meeting provided a comprehensive review of the company's Q1 marketing achievements and outlined the sales objectives for the second quarter. Senior company leaders, the sales team, and heads of various functional departments gathered together to collaboratively explore strategies for achieving and surpassing this year's marketing targets.
2025-03-23
15
2025-03
Protecting Investors: Keyuan in Action | Stay Away from Illegal Stock Recommendations, Refuse Off-Exchange Margin Financing
2025-03-15
11
2025-03
To inspire employees' innovative thinking and empower them toward the goals of improving quality, reducing costs, and boosting efficiency—thereby enhancing the company's overall operational effectiveness—Keyuan Pharmaceutical launched a company-wide proposal improvement campaign in the fourth quarter of 2024. Since the initiative was kicked off, it has received an enthusiastic response from employees, who have actively submitted valuable suggestions tailored to their respective areas of work. These proposals span across multiple dimensions, including production, management, technology, and safety, vividly demonstrating employees' deep insights into the company's development as well as their strong sense of ownership and commitment.
2025-03-11
08
2025-03
The Chinese heritage has left behind a glorious reputation, and women have powerfully upheld half the sky. To celebrate the 2025 International Women's Day on March 8, showcase the remarkable spirit of women, strengthen team cohesion, and foster a positive atmosphere of respect and care for female employees, Keyuan Pharmaceutical (stock code: 301281.SZ) specially organized a fun-filled event that drew enthusiastic participation from all female staff members across the company.
2025-03-08
05
2025-03
Today is Jingzhe—time when all that has been dormant finally breaks through the soil and emerges!
2025-03-05
28
2025-02
To accelerate the digital transformation process within the company and enhance management efficiency and decision-making capabilities, Keyuan Pharmaceutical organized a special training session on "Application of DeepSeek AI Tools" on the 26th. All middle-level and higher-level managers from the company participated in the training.
2025-02-28
28
2025-02
Beijing Nuokanda Pharmaceutical Technology Co., Ltd. is an innovation-driven, full-chain pharmaceutical CRO enterprise specializing in formulation technology platforms tailored to clinical needs. It is recognized as a National High-Tech Enterprise, a National Intellectual Property Demonstration Enterprise, and hosts a Postdoctoral Research Station. For six consecutive years, the company has been ranked among the top 20 "China's Top 20 Pharmaceutical R&D Companies" by the All-China Federation of Industry and Commerce, and it has undertaken or participated in two key national major new drug development projects under the 13th Five-Year Plan. In 2023, Keyuan Pharmaceutical acquired a 12% stake in Nuokanda, making it the company's second-largest shareholder. Today, Nuokanda has become Keyuan Pharmaceutical's Beijing-based R&D hub.
2025-02-28
28
2025-02
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline